These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22441169)

  • 1. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction.
    Naji A; Menier C; Maki G; Carosella ED; Rouas-Freiss N
    Leukemia; 2012 Aug; 26(8):1889-92. PubMed ID: 22441169
    [No Abstract]   [Full Text] [Related]  

  • 2. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
    Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
    Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse.
    Favier B; Lemaoult J; Lesport E; Carosella ED
    FASEB J; 2010 Mar; 24(3):689-99. PubMed ID: 19841038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-G and HLA-E in patients with juvenile idiopathic arthritis.
    Prigione I; Penco F; Martini A; Gattorno M; Pistoia V; Morandi F
    Rheumatology (Oxford); 2011 May; 50(5):966-72. PubMed ID: 21186170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms.
    Dorfman DM; Shahsafaei A
    Am J Clin Pathol; 2010 Nov; 134(5):726-33. PubMed ID: 20959655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
    LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
    FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors.
    HoWangYin KY; Loustau M; Wu J; Alegre E; Daouya M; Caumartin J; Sousa S; Horuzsko A; Carosella ED; LeMaoult J
    Cell Mol Life Sci; 2012 Dec; 69(23):4041-9. PubMed ID: 22802125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4.
    Wu CL; Svendsen SG; Riviere A; Desgrandchamps F; Carosella ED; LeMaoult J
    Hum Immunol; 2016 Sep; 77(9):720-6. PubMed ID: 26874236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the activation state of alpha4beta1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma.
    García-Gila M; Cabañas C; García-Pardo A
    FEBS Lett; 1997 Dec; 418(3):337-40. PubMed ID: 9428740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine nitration in the human leucocyte antigen-G-binding domain of the Ig-like transcript 2 protein.
    Díaz-Lagares A; Alegre E; Arroyo A; Corrales FJ; González A
    FEBS J; 2009 Aug; 276(15):4233-43. PubMed ID: 19583775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
    Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
    Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B lymphocyte stimulator: a new target for treating B cell malignancies.
    Sun J; Lin Z; Li Y; Shen BF
    Chin Med J (Engl); 2008 Jul; 121(14):1319-23. PubMed ID: 18713555
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential expression of HLA-G and ILT-2 receptor in human tuberculosis: Localized versus disseminated disease.
    Saurabh A; Thakral D; Mourya MK; Singh A; Mohan A; Bhatnagar AK; Mitra DK; Kanga U
    Hum Immunol; 2016 Sep; 77(9):746-53. PubMed ID: 26776460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD74 is expressed by multiple myeloma and is a promising target for therapy.
    Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
    Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Mouse Models of B Cell Malignancies.
    Perez-Chacon G; Vincent-Fabert C; Zapata JM
    Front Immunol; 2021; 12():789901. PubMed ID: 34777400
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunosuppressive molecule HLA-G and its clinical implications.
    González A; Rebmann V; LeMaoult J; Horn PA; Carosella ED; Alegre E
    Crit Rev Clin Lab Sci; 2012; 49(3):63-84. PubMed ID: 22537084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.
    Buggy JJ; Elias L
    Int Rev Immunol; 2012 Apr; 31(2):119-32. PubMed ID: 22449073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing B-malignancies: relevance for the pathogenesis.
    Roué G; Krieger S; Florent M; Roussel M; Duquesne F; Troussard X; Pichereau V; Sola B
    Leukemia; 2003 Mar; 17(3):652-5. PubMed ID: 12646964
    [No Abstract]   [Full Text] [Related]  

  • 19. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
    Huynh T; Rodriguez-Rodriguez S; Danilov AV
    Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.
    Menendez P; Vargas A; Bueno C; Barrena S; Almeida J; De Santiago M; López A; Roa S; San Miguel JF; Orfao A
    Leukemia; 2004 Mar; 18(3):491-8. PubMed ID: 14724650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.